Context Therapeutics (CNTX) Total Liabilities (2020 - 2026)

Context Therapeutics has disclosed Total Liabilities across 7 years of filings, most recently posting $6.7 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $6.7 million, up 235.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.7 million (up 235.73% YoY), and the FY2025 annual result was $8.0 million, up 180.37% from the prior year.
• Total Liabilities came in at $6.7 million for Q1 2026 at Context Therapeutics, down from $8.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $8.0 million in Q4 2025 to a low of $1.6 million in Q2 2024.
• The 5-year median for Total Liabilities is $3.2 million (2023), against an average of $3.8 million.
• Across the five-year window, Total Liabilities plunged 90.63% in 2022 and soared 235.73% in 2026, its largest moves.
• Context Therapeutics' Total Liabilities stood at $3.2 million in 2022, then jumped by 30.68% to $4.2 million in 2023, then sank by 31.76% to $2.9 million in 2024, then surged by 180.37% to $8.0 million in 2025, then declined by 17.0% to $6.7 million in 2026.
• The last three Total Liabilities figures came in at $6.7 million (Q1 2026), $8.0 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.